The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain

Molecular and Cellular Neuroscience

Volumn 18, Issue 3, 2001, Pages 247-258

  Marvanová, Markéta ^a   Lakso, Merja ^a   Pirhonen, Jarmo ^b   Nawa, Hiroyoki ^c   Wong, Garry ^a   Castrén, Eero ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b IT Center for Science   (Finland)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MEMANTINE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; TYROSINE KINASE RECEPTOR;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; IN SITU HYBRIDIZATION; LIMBIC CORTEX; MALE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0034764208     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcne.2001.1027     Document Type: Article

References (73)

1. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo
2. Anterograde transport of brain-derived neurotrophic factor and its role in the brain
3. Neurotrophin trafficking by anterograde transport
4. 125I]NT-3
5. Truncated and catalytic isoforms of trkB are co-expressed in neurons of rat and mouse CNS
6. The Trk family of neurotrophin receptors
7. Functions of brain-derived neurotrophic factor, insulin-like growth factor-1 and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons
8. Selective binding and internalisation by truncated receptors restrict the availability of BDNF during development
9. Intracerebroventricular administration of brain-derived neurotrophic factor in adult rats affects analgesia and spontaneous behaviour but not memory retention in a Morris water maze task
10. Light regulates expression of brain-derived neurotrophic factor mRNA in rat visual cortex
11. Differential effects of MK-801 on the brain-derived neurotrophic factor mRNA levels in different regions of rat brain
12. Brain-derived neurotrophic factor messenger RNA is expressed in the septum, hypothalamus and in adrenergic brain stem nuclei of adult rat brain and is increased by osmotic stimulation in the paraventricular nucleus
13. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: Evidence for anterograde axonal transport
14. The role of neuronal growth factors in neurodegenerative disorders of the human brain
15. Glutamate in CNS disorders
16. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies
17. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial
18. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling
19. Identification of cells in rat brain and peripheral tissues expressing mRNA for members of the nerve growth factor family
20. Ageing and Parkinson's disease: Substantia nigra regional selectivity
21. BDNF up-regulates TrkB protein and prevents the death of CA1 neurons following transient forebrain ischemia
22. Characterization of glial trkB receptors: Differential response to injury in the central and peripheral nervous systems
23. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration
24. Requirement for BDNF in activity-dependent survival of cortical neurons
25. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study
26. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo
27. Truncated trkB.T1 is dominant negative inhibitor of trkB.TK+ mediated cell survival
28. Neurotrophic factor therapy for nervous system degenerative diseases
29. Pharmacology of neurotrophic factors
30. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain
31. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra
32. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
33. The trkB tyrosine protein kinase gene codes for a second neurogenic receptor that lacks the catalytic kinase domain
34. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin-3
35. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study
36. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy
37. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties
38. Parkinson's disease. First of two parts
39. Parkinson's disease. Second of two parts
40. Physiology of the neurotrophins
41. Expression of a dominant negative TrkB receptor, Ti, reveals a requirement for presynaptic signaling in BDNF-induced synaptic potentiation in cultured hippocampal neurons
42. Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents
43. In vitro and in vivo methods for evaluating actions of cytokines on nerve growth factor production in central nervous system
44. Neurotrophic growth factors and neurodegenerative diseases: Therapeutic potential of the neurotrophins and ciliary neurotrophic factor
45. Rate of cell death in parkinsonism indicates active neuropathological process
46. Increased production of the TrkB protein tyrosine kinase receptor after brain insults
47. TrkB, a neural receptor protein-tyrosine kinase: Evidence for a full-length and two truncated receptors
48. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia
49. Changes in cytokines and neurotrophins in Parkinson's disease
50. BDNF protein measured by a novel enzyme immunoassay in normal brain and after seizure: Partial disagreement with mRNA levels
51. Expression and function of TrkB variants in developing sensory neurons
52. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
53. NMDA antagonist neurotoxicity-mechanism and prevention
54. Glutamate in CNS disorders as a target for drug development: An update
55. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data
56. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan)
57. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease
58. Widespread expression of BDNF but not NT3 by target areas of basal forebrain cholinergic neurons
59. Mouse astrocytes store and deliver brain-derived neurotrophic factor using the non-catalytic gp95trkB receptor
60. Transgenic mice overexpressing truncated trkB neurotrophin receptors in neurons show increased susceptibility to cortical injury after focal cerebral ischemia
61. Expression of neurotrophins by midbrain dopaminergic neurons
62. Brain-derived neurotrophic factor increases the electrical activity of pars compacta dopamine neurons in vivo
63. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine
64. A single intramesencephalic injection of brain-derived neurotrophic factor induces persistent rotational asymmetry in rats
65. Neurotrophic factor in Alzheimer's and Parkinson's disease brain
66. Antidepressants for the new millennium
67. Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity
68. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: Involvement of the glutathione system
69. Neurotrophins and neuronal plasticity
70. Rapid nuclear responses to target-derived neurotrophins require retrograde transport of ligand-receptor complex
71. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome
72. In situ hybridization with synthetic oligonucleotide probes